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Abstract
TRAIL is a death receptor ligand that induces cell death preferentially in tumor cells. Recombinant soluble TRAIL, however,
performs poorly as an anti-cancer therapeutic because oligomerization is required for potent biological activity. We
previously generated a diabody format of tumor-targeted TRAIL termed DbaEGFR-scTRAIL, comprising single-stranded TRAIL
molecules (scTRAIL) and the variable domains of a humanized variant of the EGFR blocking antibody Cetuximab. Here we
define the bioactivity of DbaEGFR-scTRAIL with regard to both EGFR inhibition and TRAIL receptor activation in 3D cultures of
Caco-2 colorectal cancer cells, which express wild-type K-Ras. Compared with conventional 2D cultures, Caco-2 cells
displayed strongly enhanced sensitivity toward DbaEGFR-scTRAIL in these 3D cultures. We show that the antibody moiety of
DbaEGFR-scTRAIL not only efficiently competed with ligand-induced EGFR function, but also determined the apoptotic
response by specifically directing DbaEGFR-scTRAIL to EGFR-positive cells. To address how aberrantly activated K-Ras, which
leads to Cetuximab resistance, affects DbaEGFR-scTRAIL sensitivity, we generated stable Caco-2tet cells inducibly expressing
oncogenic K-RasG12V. In the presence of doxycycline, these cells showed increased resistance to DbaEGFR-scTRAIL, associated
with the elevated expression of the anti-apoptotic proteins cIAP2, Bcl-xL and FlipS. Co-treatment of cells with the Smac
mimetic SM83 restored the DbaEGFR-scTRAIL-induced apoptotic response. Importantly, this synergy between DbaEGFR-
scTRAIL and SM83 also translated to 3D cultures of oncogenic K-Ras expressing HCT-116 and LoVo colorectal cancer cells.
Our findings thus support the notion that DbaEGFR-scTRAIL therapy in combination with apoptosis-sensitizing agents may
be promising for the treatment of EGFR-positive colorectal cancers, independently of their KRAS status.
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Introduction
Colorectal cancer (CRC) is one of the most prevalent cancers
worldwide and especially in patients with advanced CRC survival
rates are low [1]. In addition to chemotherapy, targeted therapies
have entered the clinic. Currently, the EGFR (epidermal growth
factor receptor) blocking antibodies Cetuximab and Panitumumab
are approved for the treatment of metastatic CRC in combination
with chemotherapy or as a maintenance therapy in chemo-
refractory tumors [2,3].
EGFR, also known as ErbB1 or HER1, is associated with the
pathogenesis of various human epithelial cancers. This receptor
tyrosine kinase comprises an extracellular ligand-binding domain,
a single membrane spanning region, and a cytoplasmic tyrosine
kinase domain [4,5]. Upon binding of ligands such as EGF and
TGF-a, the receptor homo- and heterodimerizes preferentially
with the family member ErbB2/HER2 leading to receptor
activation and transphosphorylation of specific tyrosines within
the cytoplasmic tails. These phosphotyrosines provide docking
sites for intracellular signaling molecules that trigger the activation
of MAPK and PI3K pathways, which mediate biological responses
such as proliferation, migration and survival [5,6]. Cetuximab
competes with EGFR ligands for receptor binding, thereby
repressing receptor phosphorylation and the activation of down-
stream signaling [1].
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The different genetic alterations found in CRC limit the efficacy
of anti-EGFR therapies. Nearly 40% of all CRC cases harbor
activating mutations in the KRAS gene. Receptor tyrosine kinase
signaling converges at the level of the small GTPase Ras, a master
regulator of both, MAPK and PI3K pathways. The most frequent
mutations occur at codon 12 or 13, leading to constitutive Ras
activation and, consequently, reduced or no response to Cetux-
imab treatment [7,8].
TRAIL (tumor necrosis factor-related apoptosis-inducing li-
gand) is a death ligand that induces apoptosis preferentially in
tumor cells via the death receptors TRAILR1 and TRAILR2, also
known as DR4 and DR5, respectively [9]. Binding of TRAIL
triggers receptor oligomerization, followed by the recruitment of
adaptor proteins and the formation of the death-inducing signaling
complex. This ultimately leads to the activation of initiator
caspases and consecutive activation of effector caspases, resulting
in apoptotic cell death [10]. Clinical trials using recombinant
TRAIL confirmed the low toxicity to normal tissue, but
therapeutic effects were insufficient [11,12]. To overcome these
limitations protein engineering approaches have aimed at
improving bioactivity while maintaining tumor selectivity. Correct
trimerization and zinc coordination of recombinant TRAIL seem
to be crucial for biological activity [13]. Accordingly, the design of
a single polypeptide chain comprising the extracellular domains of
three TRAIL monomers (scTRAIL) enhanced the bioactivity of
the recombinant molecule [14]. Such molecules can further be
fused to antibodies directed against tumor markers. We previously
showed that the fusion of scTRAIL to a single-chain antibody
fragment (scFv) functionally mimicked natural membrane-bound
TRAIL and was more effective than scTRAIL alone [14]. The
introduction of a diabody configuration based on the humanized
variable regions of Cetuximab (DbaEGFR-scTRAIL) resulted in an
even higher bioactivity of recombinant TRAIL both in vitro and
in vivo, as seen by the strong reduction of tumor size and
prolonged survival of nude mice carrying Colo205 xenografts [15].
Apart from its tumor targeting effect, the EGFR-directed
antibody moiety contained within the DbaEGFR-scTRAIL mole-
cule may actively interfere with EGFR function while simulta-
neously stimulating apoptosis. To dissect the contribution of
EGFR blockade to the bioactivity of DbaEGFR-scTRAIL we used
the EGFR-positive Caco-2 CRC cell line, which harbors
mutations in APC, p53, and SMAD4 but is wild-type for the
MAPK and PI3K pathways [16]. To mimic more closely the
in vivo situation, Caco-2 cells were grown in 3D collagen/matrigel
cultures where they form fully differentiated polarized cysts [17].
Growth conditions are known to influence the balance of survival
and apoptosis signals, highlighting the need for studying drug
treatment and resistance mechanisms not only in conventional 2D
cultures [18]. Indeed, our results show that cultivation of Caco-2
cells in a 3D matrix renders cells TRAIL-sensitive. We further
demonstrate that EGFR signaling contributes to Caco-2 cell
proliferation and can be blocked by pharmacological EGFR
inhibition. The importance of the EGFR-specific antibody moiety
for the efficient targeting of DbaEGFR-scTRAIL is underscored by
the fact that low EGFR levels characterize the cell subpopulation
that survives DbaEGFR-scTRAIL treatment. Moreover, although
insensitive to EGFR blockade per se, EGFR-positive Ras mutant
CRC cells are targeted and sensitized to DbaEGFR-scTRAIL-
induced apoptosis by co-treatment with the Smac mimetic SM83.
The potent cytotoxic activity of DbaEGFR-scTRAIL revealed in
this study thus lends support for its further development as an anti-
cancer therapeutic for the treatment of CRC.
Materials and Methods
Antibodies and reagents
Antibodies used were monoclonal rabbit anti-pEGFR (Y1068)
(1:1000), monoclonal rabbit anti-caspase-3 (1:1000), polyclonal
rabbit anti-TRAILR2 (1:500), polyclonal rabbit anti-pERK
(T202/Y204) (1:1000), monoclonal rabbit anti-pAKT (T308)
(1:1000), polyclonal rabbit anti-cIAP1 (1:1000), monoclonal rabbit
anti-cIAP2 (1:1000), monoclonal mouse anti-ERK (1:1000),
monoclonal mouse anti-AKT (pan) (1:1000), monoclonal mouse
anti E-Cadherin (1:250), monoclonal mouse anti-Smac (1:1000),
polyclonal rabbit anti-Bcl-2 (1:1000), monoclonal rabbit anti-Bcl-
xL (1:400) and monoclonal rabbit anti-survivin (1:1000) (all from
Cell Signaling, Danvers, MA, USA), monoclonal mouse anti-xIAP
(1:400), monoclonal mouse anti-Ras (1:200) (BD, CA, SanJose,
USA), monoclonal mouse anti-FlipS/L (1:400) and polyclonal
rabbit anti-TRAILR1 (1:1000) (Santa Cruz Biotechnology, Dallas,
TX, USA), monoclonal mouse anti-EGFR (1:500) (Thermo
Scientific, Fremont, MA, USA), monoclonal mouse anti-alpha-
tubulin (1:5000) (Sigma-Aldrich, St Louis, MO, USA), and
monoclonal mouse anti-GFP (1:1000) (Roche Applied Science,
Mannheim, Germany). HRP-labeled secondary anti-mouse and
anti-rabbit IgG antibodies (1:10000) were from GE Healthcare
(Buckinghamshire, UK). Alexa Fluor 488- and 546-labeled
secondary anti-mouse and anti-rabbit IgG antibodies (1:500) and
Alexa Fluor 633-labeled phalloidin (1:100) were from Invitrogen
(Carlsbad, CA, USA). DAPI was from Sigma-Aldrich, Z-VAD-
FMK was from Bachem AG (Bubendorf, Switzerland), and
Cetuximab from Merck (Darmstadt, Germany). DbaEGFR-
scTRAIL was produced in HEK293 cells and purified from cell
culture supernatants [15]. The synthesis and purification of SM83
was described previously [19,20].
Cell culture
Caco-2, HCT-116, and LoVo cell lines were cultured in RPMI
1640 (Invitrogen), and Caco-2tet cells in DMEM (Invitrogen)
supplemented with 10% FCS (PAA Laboratories, Co¨lbe, Ger-
many). Cell lines were incubated in a humidified atmosphere of
5% CO2 at 37uC. For growth factor dependent assays cells were
cultured in medium containing 2% FCS plus 10 ng/ml EGF
(Sigma-Aldrich) and TGF-a (Peprotech, Rocky Hill, NJ, USA).
For growth in 3D, cells were seeded on a bed of growth factor
reduced matrigel (BD) and PureCol-S collagen (Advanced
Biomatrix, San Diego, CA, USA) (1:1) and overlayed with growth
medium containing 2% matrigel. Lumen expansion was induced
by addition of 100 ng/ml choleratoxin (CTX; Sigma Aldrich) at
day 3 post seeding.
Generation of Caco-2tet RasG12V cells
The pTET/KRASG12V-IRES-GFP-bsr expression vector,
which allows the doxycycline-inducible expression of K-RasG12V,
was generated by recovering the K-RasG12V open reading frame
from pBABE-K-RasG12V (Addgene) by BamHI digestion, followed
by the insertion into the BglII-linearized pMIG vector [21]. The
resulting K-RasG12V-IRES-GFP cassette was amplified by PCR
using oligonucleotides containing flanking NotI sites, which were
used for subcloning into pSC-A-amp/kan (Stratagene, La Jolla,
CA, USA). Subsequently, the K-RasG12V-IRES-GFP cassette was
cloned via NotI digestion into the pTET-bsr vector [22], yielding
pTET/K-RasG12V-IRES-GFP-bsr. To achieve doxycycline-induc-
ible expression of oncogenic K-Ras, Caco-2tet cells, stably
expressing the doxycycline-inducible system components rtTA
and rtTS [21], were transfected with the AhdI-linearized pTET/
K-RasG12V-IRES-GFP-bsr vector by electroporation. Following
DbaEGFR-scTRAIL in a 3D CRC Model
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selection with blasticidine S (5 mg/ml) and puromycin (5 mg/ml),
resistant cell pools were screened for efficient induction of K-
RasG12V expression. Transgene expression was induced by
addition of 2 mg/ml doxycycline (Merck).
FACS analysis
Analysis of transgene expression of the Caco-2tet cells was
performed after 72 dox treatment. Cells were washed, resuspended
in PBS containing 2% FCS and 0.01% sodium azide, and
analyzed using an EPICS FC500 (Beckman Coulter, Krefeld,
Germany). Post-acquisition data analysis was performed using
FlowJo software (Tree Star; Ashland, OR, USA).
Western blotting
Cells were lysed in RIPA buffer (50 mM Tris (pH 7.5), 150 mM
NaCl, 1% Triton-X 100, 0.5 sodium deoxycholate, 0.1% SDS,
1 mM sodium orthovanadate, 10 mM sodium fluoride and
20 mM b-glycerophosphate plus Complete protease inhibitors
(Roche)). For 3D lysates, cells were cultured on pure matrigel
without collagen. Spheroids were isolated after 4 days using Cell
Recovery Solution (BD) and lysed in RIPA buffer. Lysates were
clarified by centrifugation, equal amounts of protein were
separated by SDS–PAGE (NuPAGE Novex Bis-Tris Gel; Invitro-
gen) and transferred to nitrocellulose membrane (iBlot Gel
Transfer Stacks; Invitrogen). Membranes were blocked with
0.5% blocking reagent (Roche) in PBS containing 0.1% Tween-
20 and incubated with primary antibodies, followed by HRP-
conjugated secondary antibodies. Visualization was done with
ECL detection system (Pierce, Rockford, IL, USA).
MTT, cytotoxicity, and caspase 3/7 activity assays
For 2D cultures, 2.56103 cells/well in 100 ml medium were
plated into uncoated 96-well plates. For 3D cultures, 56103 cells/
well were seeded into matrigel/collagen-coated 96-well plates in
100 ml medium containing 2% matrigel. Viability was determined
by addition of 10 ml 3-(4,5-dimethylthiazol-2yl-)2,5-diphenyl
tetrazolium (MTT; Roth, Karlsruhe, Germany) solution (5 mg/
ml) followed by incubation for 3 h. Cells were lysed by addition of
100 ml 50% dimethylformamide containing 10% SDS and
absorbance was measured at 570 nm using the multimode reader
Infinite 200 PRO (Tecan, Ma¨nnedorf, Switzerland). Cytotoxicity
was measured using the CytoTox-Glo Cytotoxicity Assay from
Promega (Madison, WI, USA). The activity of dead-cell protease
in the culture was determined by addition of 50 ml luminogenic
substrate. After 15 min incubation at RT, luminescence was
measured using the multimode reader Infinite 200 PRO (Tecan),
followed by cell lysis and measurement of total luminescence for
normalization.
Caspase 3/7 activity was determined using the Caspase-Glo3/7
Assay from Promega (Madison, WI, USA) by addition of 70 ml
luminogenic substrate containing the DEVD sequence. After
30 min incubation at RT, luminescence was measured using the
multimode reader Infinite 200 PRO (Tecan).
Tunel staining
DNA strand breaks were analyzed with the in situ cell death
detection kit (TMR) from Roche. Cells were fixed with 4% PFA
for 1 h at RT and permeabilized with 0.1% Triton-X 100 in 0.1%
sodium citrate for 2 min at RT. Labeling was performed
according to the manufacturer’s protocol for 1 h at 37uC. Nuclei
were counterstained with DAPI. Slides were mounted in
Fluoromount G (Southern Biotechnology, Birmingham, AL,
USA) and analyzed on a confocal laser scanning microscope
(LSM 700; Zeiss, Oberkochen, Germany). Images were processed
with the ZEN software (Zeiss). Tunel-positive cells were counted
using ImageJ (W. Rasband, National Institute of Health, USA;
Version 1.48).
Immunofluorescence microscopy
Cells grown in 3D on matrigel/collagen coated 8-well glass
chamber slides (BD) were fixed with 4% PFA for 15 min,
permeabilized with PBS containing 0.1% Triton X-100 for
10 min and blocked with 5% goat serum (Invitrogen) in PBS
containing 0.1% Tween-20. Cells were then incubated with
primary antibodies in blocking buffer (2 h at RT), washed with
PBS containing 0.1% Tween-20 and incubated with secondary
antibody in blocking buffer (2 h at RT). F-Actin and nuclei were
counterstained with Alexa Fluor 633-labeled phalloidin and DAPI.
Slides were mounted in Fluoromount G and analyzed on a
confocal laser scanning microscope (LSM 700; Zeiss, Oberkochen,
Germany) using 488, 561 and 633 nm excitation with oil objective
lenses Plan-Apochromat 63x/1.40 DIC M27. Images were
processed with the ZEN software (Zeiss).
Statistical analysis
Data are expressed as mean (6 S.E.M.), and ‘n’ refers to the
number of independent experiments. Statistical significance was
evaluated by t-test, and one-way ANOVA followed by Tukey’s
post-test (GraphPad Prism version 4.03; GraphPad Software Inc.,
La Jolla, CA). p-values below 0.05 were considered significant
(*p,0.05; **p,0.01; ***p,0.001; ns, p.0.05).
Results
In 3D matrigel cultures, Caco-2 cells differentiate into polarized
cysts composed of a single cell layer surrounding a central lumen
[17,21], reflecting the organotypic organization of the colon.
Because these cells are EGFR-positive and express wild-type Ras,
they represent an ideal model system for studying the combined
effect of EGFR inhibition and an apoptosis-inducing agent such as
TRAIL. To first test the efficacy of DbaEGFR-scTRAIL, Caco-2
cells were cultured for three days in 3D in medium containing
10% FCS before addition of DbaEGFR-scTRAIL followed by
MTT measurements three days later. In these cultures, relatively
low doses of DbaEGFR-scTRAIL caused a significant reduction of
cell viability which was associated with the disruption of cysts and
the formation of apoptotic bodies (Fig. 1a, b), scTRAIL alone or in
combination with Cetuximab failed to elicit a cytotoxic response in
Caco-2 3D cultures (Fig. S1), supporting our previous data that the
diabody-mediated dimeric structure of DbaEGFR-scTRAIL confers
superior bioactivity over scTRAIL [15]. Interestingly, in conven-
tional 2D cell cultures on plastic, Caco-2 cells were highly resistant
to DbaEGFR-scTRAIL treatment (Fig. 1a, b), in line with a
previous report using recombinant human TRAIL [23]. Pretreat-
ment of the Caco-2 3D cultures with Z-VAD, a pan-caspase
inhibitor, significantly reduced the cytotoxic effect of DbaEGFR-
scTRAIL (Fig. 1c), and the induction of apoptosis by DbaEGFR-
scTRAIL was confirmed by the analysis of DNA fragmentation by
Tunel staining (Fig. 1d, e). Additionally, compared with 2D
cultures, the dose-dependent activation of caspases 3/7 in response
to DbaEGFR-scTRAIL was significantly increased in 3D cultures
(Fig. 1f). This difference in sensitivity toward DbaEGFR-scTRAIL
in 3D versus 2D cultures could not be attributed to changes in
EGFR or TRAILR1/2 expression (Fig. 1g, h). Unfortunately,
because the decoy receptors DcR1, DcR2 could not be detected
by immunoblotting with the antibodies available, expression
changes in these receptors could not be ruled out. Analysis of
DbaEGFR-scTRAIL in a 3D CRC Model
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key signaling pathways revealed that, in 3D cultures, the activity of
the PI3K pathway was suppressed compared with cells grown in
2D as measured by phospho-Akt levels whereas the ERK/MAPK
pathway was upregulated as seen by increased ERK1/2
phosphorylation (Fig. 1g, h). However, inhibition of PI3K by
LY294002 in 2D cultures was not sufficient to sensitize cells to
DbaEGFR-scTRAIL (data not shown), indicating a more complex
scenario in 3D cultures. Together, these results underscore the
impact of the culture conditions on the cellular response toward
apoptosis-inducing agents.
We next investigated how the presence of EGFR ligands
affected growth and differentiation of Caco-2 cells in the 3D
cultures. Cells were seeded in matrigel cultures containing low
serum (2%) in the presence of EGF or TGF-a, ensuring that
proliferation was mainly driven via EGFR signaling. MTT activity
measurements after six days of cultivation indicated that EGF and
TGF-a enhanced the proliferation of Caco-2 cells compared with
control cells grown in low serum only (Fig. 2a). Microscopic
analysis revealed that in the presence of EGF and TGF-a Caco-2
cysts were larger and contained more cells (Fig. 2b). Notably, the
addition of EGFR ligands did not interfere with differentiation, as
judged by the typical apical distribution of F-actin and the
formation of a cell-free lumen (Fig. 2b). To address how EGFR
blockade affected basal and EGFR ligand-induced proliferation of
established Caco-2 cysts, we treated the cells three days after
seeding with Cetuximab (0.5 mM) and analyzed the cultures three
days later. Compared with the control, in these cultures the MTT
activity was significantly reduced by 35–50%, but cells were still
viable, did not show any signs of apoptosis and only negligibly
increased cytotoxicity (Fig. 2c–e; S1d). This indicates that EGFR
activation contributes to basal proliferation, but is not required for
survival. Cetuximab also potently inhibited proliferation in the
presence of EGF and TGF-a as seen by the reduction of MTT
activity and the reduced size of the cysts (Fig. 2c, d). Together
these experiments demonstrate that proliferation of Caco-2 cells in
3D cultures can be driven by EGFR signaling and is sensitive to
pharmacological EGFR inhibition, and can thus potentially be
suppressed by DbaEGFR-scTRAIL.
EGFR activation not only stimulates cell proliferation but can
also protect from TRAIL-induced apoptosis [24]. Therefore, we
next explored the efficacy of DbaEGFR-scTRAIL in the presence of
EGFR ligands. Immunoblotting of lysates of EGF- and TGF-a-
stimulated cells revealed a similar degree of suppression of ligand-
induced EGFR phosphorylation by either Cetuximab or
DbaEGFR-scTRAIL pretreatment (Fig. 3a, b), indicating the
efficient competition of the diabody moiety with the EGFR
ligands. This could also be confirmed in 3D cultured Caco-2 cells
stimulated with EGF (Fig. S2). Accordingly, EGF and TGF-a had
no protective effect on viability in 3D (Fig. 3c) nor were these
ligands able to interfere with caspase activation (Fig. 3d),
demonstrating that DbaEGFR-scTRAIL activity is not limited by
the presence of EGFR ligands. To understand in more detail
resistance mechanisms toward DbaEGFR-scTRAIL, we re-isolated
cysts from untreated and DbaEGFR-scTRAIL-treated 3D matrigel
cultures followed by immunoblotting of cell lysates (Fig. 3f, g).
Interestingly, lysates derived from surviving cysts (Fig. 3e, arrows)
revealed that these DbaEGFR-scTRAIL-insensitive cells contained
especially low EGFR levels. Of note, TRAIL receptor levels in
these cells were similar to those in untreated cells, suggesting that
the distribution of EGFR expression in the cell population strongly
impacts DbaEGFR-scTRAIL sensitivity (Fig. 3f, g). Thus, although
the diabody moiety does not actively contribute to apoptosis and
mainly has a growth inhibitory function in Caco-2 3D cultures, the
EGFR-directed targeting is important to increase the local TRAIL
concentration and trigger an efficient apoptotic response.
Approximately 40% of all CRC tumors harbor an active
mutation in the KRAS gene, leading to constitutive ERK/MAPK
activation and loss of responsiveness to Cetuximab [7], whereas
TRAIL sensitivity may be increased [25]. To investigate the
influence of oncogenic Ras on DbaEGFR-scTRAIL-induced
cytotoxicity, we generated stable Caco-2 cells inducibly expressing
K-RasG12V. In these cells, doxycycline induces the bi-cistronic
expression of the oncogene and GFP, whereas vector control cells
express GFP only. Three days after doxycycline addition, more
than 85% of the Caco-2tet cells were GFP positive by FACS
analysis (Fig. 4a). Immunoblotting of Caco-2tet K-RasG12V cell
lysates confirmed Ras overexpression along with that of GFP,
concomitant with strong ERK phosphorylation, whereas vector
control cells expressed only GFP (Fig. 4b). When these cells were
seeded into 3D cultures in the absence of doxycycline, both Caco-
2tet vector and K-RasG12V cells formed well-differentiated and
polarized spheroids with basolateral adherens junctions (E-
cadherin staining) and apical F-actin accumulation around a
cell-free lumen. Addition of doxycycline had no effect on the
morphology of the control cells, whereas the K-RasG12V express-
ing cells formed multi-luminal spheroids that lacked distinct
polarization (Fig. 4c). These differentiation defects caused by K-
RasG12V are in accordance with a recent report by Magudia et al.
(2012) [16].
To determine the effects of K-RasG12V expression on DbaEGFR-
scTRAIL induced cytotoxicity, 3D cultures were treated with
doxycycline for three days. Compared with the control cells,
viability measurements revealed decreased sensitivity of oncogenic
Ras expressing cells to DbaEGFR-scTRAIL (Fig. 5a). To confirm
that this partial resistance was due to reduced apoptosis, we
performed Tunel stainings and measured caspase 3/7 activation.
Indeed, K-RasG12V cells showed strongly reduced DNA fragmen-
tation after treatment with 1 nM DbaEGFR-scTRAIL (Fig. 5b) and
only a weak induction of caspase activity (Fig. 5c). This resistance
was not due to EGFR or TRAILR1/2 downregulation. In fact,
immunoblotting of 3D cell lysates of the vector and K-RasG12V
cells revealed increased TRAILR2 protein levels (Fig. 5d, e), in
agreement with previous reports [25,26]. Oncogenic Ras can
interfere with apoptosis at multiple levels, for example, by
activation of PI3K survival signaling and changes in transcrip-
tional programs [27,28]. Indeed, in 2D cultures, we observed
increased Akt phosphorylation in K-RasG12V expressing cells. In
3D cultures, however, the suppression of the PI3K-Akt pathway
appears to be dominant (see Fig. 1g), with K-RasG12V expression
leading to marginally elevated Akt phosphorylation only (data not
shown). Interestingly, expression analysis of selected key regulators
of the apoptotic machinery revealed significantly elevated levels of
the anti-apoptotic proteins cIAP2, FlipS, and Bcl-xL (Fig. 5d, e).
Because molecular changes occurred at different levels of the
apoptotic pathway, we sought to block K-RasG12V induced anti-
apoptotic signaling as far downstream as possible. Inhibitor of
apoptosis (IAP) proteins, such as cIAP2, interfere with apoptosis by
the direct binding, inhibition and/or degradation of caspases and
components of the Ripoptosome, and by antagonizing non-
canonical NFkappaB signaling [29]. The activity of IAP proteins is
balanced by Smac/Diablo, a protein released from mitochondria
in cells primed for apoptosis. Peptides that mimic the aminoterm-
inal IAP-binding sequence of Smac, so-called Smac mimetics,
were found to enhance the cytotoxicity of chemotherapeutic
agents and death ligands such as TRAIL [30,31]. Indeed, co-
treatment of Caco-2tet K-RasG12V cells with DbaEGFR-scTRAIL
and a previously developed highly efficient dimeric Smac mimetic,
DbaEGFR-scTRAIL in a 3D CRC Model
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Figure 1. Caco-2 3D cultures are sensitive to DbaEGFR-scTRAIL. Cells were grown in 3D or 2D in medium containing 10% FCS. (a) Three days
post seeding, cultures were treated with DbaEGFR-scTRAIL. Viability was measured 72 h later by MTT assay and normalized to the untreated control
(n = 3). (b) Phase contrast images of the 3D and 2D cultures described in (a) treated with the indicated concentrations of DbaEGFR-scTRAIL for 72 h
(scale bar: 50 mm). (c) Three days post seeding, 3D cultures were pretreated with 20 mM Z-VAD as indicated before addition of 1 nM DbaEGFR-scTRAIL.
Viability was measured 72 h later by MTT assay and normalized to the untreated control (ut) (n = 3). (d) 24 h after treatment, cells were fixed and
DbaEGFR-scTRAIL in a 3D CRC Model
PLOS ONE | www.plosone.org 5 September 2014 | Volume 9 | Issue 9 | e107165
SM83 [19,20], decreased cell viability by 35% compared with the
single treatments. This was efficiently blocked by Z-VAD, proving
the involvement of caspase activation in the case of the
combinatorial treatment (Fig. 6a). Tunel staining further con-
firmed the enhancement of apoptosis by SM83 (Fig. 6b). Of note,
the presence of SM83 also lowered the DbaEGFR-scTRAIL
concentration required to kill parental Caco-2 and Caco-2tet
vector cells (data not shown). Analysis of cell lysates derived from
Caco-2 3D cultures showed that SM83 incubation for 24 h led to
the complete loss of cIAP1, whereas cIAP2 levels were only slightly
decreased, and xIAP, survivin and Smac were not affected
(Fig. 6c, d). The presence of cIAP2 at this time point can be
explained by its upregulation in response to cIAP1 loss in
accordance with a previous report (Fig. S3; [32]). Nevertheless,
by regulating the overall IAP/Smac balance, SM83 appears to
restore the apoptotic response in oncogenic Ras expressing Caco-2
cells. Finally, to investigate whether our targeted combination
strategy could be transferred to CRC cell lines with endogenous
KRAS mutations, we co-treated HCT-116 and LoVo cells with
DbaEGFR-scTRAIL and SM83 in 3D cultures. These cell lines are
EGFR-positive (data not shown) and show moderate sensitivity to
DbaEGFR-scTRAIL, making them amenable to the combined
action of DbaEGFR-scTRAIL and Smac mimetics. Reminiscent of
the Caco-2tet K-RasG12V cells, HCT-116 and LoVo cells failed to
form differentiated and polarized spheroids in 3D culture (Fig. 6e,
f). Importantly, a synergistic cytotoxic effect of DbaEGFR-scTRAIL
and SM83 was observed for both cell lines when DbaEGFR-
scTRAIL was applied at a sublethal concentration (Fig. 6e, f).
Thus, based on our data we propose that EGFR-targeted
scTRAIL molecules, together with apoptosis-sensitizing agents,
stained for DNA strand breaks. Tunel-positive cells were counted (n = 2). (e) Representative pictures of the Tunel stainings described in (d), Tunel-
positive cells (red), DAPI (nuclei; blue). Shown are confocal sections (scale bar: 100 mm). (f) Three days post seeding, cultures were treated with 0.1 nM
or 1 nM DbaEGFR-scTRAIL for 24 h. Caspase 3/7 activity was measured and normalized to the respective untreated control (ut) (n = 3). (g) Four days
post seeding, lysates were generated and analyzed by immunoblotting. Shown is one representative blot of three independent experiments. Tubulin
was detected as a loading control. Specific bands are marked by arrowheads. (h) Quantification of Western blots from (g). Protein levels were
normalized to the corresponding tubulin control; levels in the 2D cultures were set as 1 (n = 3).
doi:10.1371/journal.pone.0107165.g001
Figure 2. Caco-2 3D cultures are sensitive to pharmacological EGFR inhibition. Caco-2 cells were grown in 3D cultures containing 2% FCS
in the presence of growth factors (10 ng/ml) or in 2% FCS only (con). (a) Cultures were analyzed by MTT assay at day 6 and normalized to the control
(n = 5). (b) Three days post seeding 100 ng/ml CTX was added to induce lumen expansion. Spheroids were fixed on day 6 and stained with phalloidin
(F-actin) and DAPI (nuclei). Shown are confocal sections of a representative cyst (scale bar: 10 mm). (c) Three days after seeding, 3D cultures were left
untreated or treated with 0.5 mM Cetuximab (Cet) for 72 h. Viability was determined by MTT assay and normalized to the untreated control (ut).
(n = 4) (d) Caco-2 3D cultures were left untreated or treated with 0.5 mM Cetuximab for 72 h and analyzed by phase microscopy (scale bar: 50 mm). (e)
Three days after seeding, 3D cultures were left untreated (ut) or treated with 0.5 mM Cetuximab (Cet) for 72 h. Cytotoxicity was determined using the
CytoTox-Glo Cytotoxicity Assay (n = 3).
doi:10.1371/journal.pone.0107165.g002
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may be an effective therapy for CRC independently of the KRAS
status.
Discussion
Inducing apoptosis exclusively in tumor cells, while leaving
normal tissue unharmed, is the goal of every anti-cancer drug
development. Due to its selectivity for tumor cells, TRAIL is
regarded as a promising anti-cancer therapeutic. Apoptosis
induction by TRAIL moreover does not depend on p53, the
frequent loss or mutation of which is a major cause of
chemotherapy resistance [33]. Despite these advantageous features
of TRAIL, the molecular mechanisms that govern TRAIL
sensitivity versus resistance still remain poorly understood. There
is neither a clear correlation between total TRAILR1/2 levels nor
the ratio of TRAILR1/2 and the decoy receptors DcR1, DcR2
and TRAIL sensitivity [34,35]; instead, activation of PI3K/Akt
and NFkappaB signaling pathways, and the overexpression of anti-
apoptotic proteins such as Bcl-2, IAPs and Flip have been
implicated in TRAIL resistance [36,37,9]. A better understanding
of resistance mechanisms and the identification of effective drug
combinations are thus essential for the right choice of target
patients and an optimized personalized treatment design.
Figure 3. EGFR-directed targeting determines the bioactivity of DbaEGFR-scTRAIL. (a) Caco-2 cells grown in 2D were left untreated or
treated with 4 nM DbaEGFR-scTRAIL or 4 nM Cetuximab for 15 min prior to stimulation with EGF or TGF-a (10 ng/ml) for 10 min. Phosphorylated and
total proteins were detected by immunoblotting. Shown is one representative blot of three independent experiments. Tubulin was detected as a
loading control. (b) Quantification of Western blots from (a). Phospho-EGFR levels were normalized to the corresponding total protein levels; levels in
the untreated control were set as 1 (n = 3). (c, d). Three days post seeding, Caco-2 3D cultures grown in the absence or presence of growth factors
were treated with 1 nM DbaEGFR-scTRAIL. (c) Viability was determined by MTT assay after 72 h and normalized to the respective untreated control (ut).
(n = 3) (d) Caspase 3/7 activity was measured after 24 h. Values were normalized to the corresponding untreated control (n = 3). (e) Three days post
seeding, Caco-2 3D cultures were either left untreated or treated with 5 nM DbaEGFR-scTRAIL for 72 h. Surviving cysts in the phase contrast images are
indicated by arrows (scale bar: 50 mm). (f) Lysates derived from the 3D cultures shown in (e) were analyzed by immunoblotting. Shown is one
representative blot of three independent experiments. Tubulin was detected as a loading control. Specific bands are marked by arrowheads. (g)
Quantification of Western blots from (f). Protein levels were normalized to the corresponding tubulin control; levels in the untreated cultures were set
as 1 (n = 3).
doi:10.1371/journal.pone.0107165.g003
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Here, we explored in a 3D model of CRC the mechanisms of
action of a targeted single-chain TRAIL molecule comprising an
EGFR blocking and targeting moiety derived from Cetuximab
and three TRAIL monomers. EGFR ligands have been reported
to protect epithelial cells from TRAIL-induced apoptosis, mainly
via the activation of PI3K signaling [24,38]. Treatment of CRC
cells with recombinant TRAIL was further reported to lead to
EGFR upregulation and shedding of TGF-a, resulting in the
activation of autocrine and paracrine EGFR/HER2 pro-survival
signaling [39]. Additionally, EGFR ligand shedding may also be
induced by oncogenic Ras signaling [40]. These findings provide a
rationale for combining pharmacological EGFR blockade with
TRAIL receptor agonists. Indeed, in an ErbB2/Neu tumor mouse
model the combined treatment with an ErbB2 blocking antibody
and a TRAILR2 agonistic antibody had synergistic effects [41].
Consistent with this, our data show that DbaEGFR-scTRAIL
reduced basal and EGFR ligand-induced proliferation of Caco-2
cells in 3D cultures in addition to efficiently inducing apoptosis of
EGFR-positive cells irrespective of the presence of the EGFR
ligands EGF or TGF-a.
Using Caco-2tet cells inducibly expressing K-RasG12V, we
provide evidence that oncogenic Ras protects from death receptor-
induced apoptosis. In CRC, ligand-independent activation of the
ERK/MAPK and PI3K pathways by mutant K-Ras is not only
associated with the loss of responsiveness to Cetuximab [7], but
also enhances cell proliferation and survival by interfering with the
apoptotic machinery. Specifically, KRAS mutations at codon 12
could be correlated to reduced apoptosis in vitro and lower
apoptotic indices in colorectal tumors [42]. By contrast, K-Ras has
also been reported to promote apoptosis through the upregulation
of TRAILR2 [25,28]. Intriguingly, in doxycycline-treated Caco-
2tet RasG12V cells TRAILR2 was also found to be upregulated,
however, this was not sufficient to trigger apoptosis. It appears that
the additional molecular changes in the apoptotic pathway
downstream of TRAIL receptors, such as the elevation of FlipS,
Bcl-xL and cIAP2 overcome TRAILR2 upregulation, ultimately
favoring cell survival. The balance of pro- and anti-apoptotic
signaling molecules thus appears to determine the cellular
outcome in a cell type-dependent manner.
This balance between proliferation, survival and death is not
only dictated by cell-intrinsic factors, but is also profoundly
affected by the cellular environment. Our data reveal that Caco-2
cells display dramatically increased sensitivity to DbaEGFR-
scTRAIL-induced apoptosis in 3D collagen/matrigel cultures,
which cannot simply be explained by changes in EGFR or
TRAIL1/2 receptor levels. Because clustering is important for the
stimulation of TRAIL receptor activation, the basolateral locali-
zation of both EGFR and TRAIL receptors may create a more
densely packed signaling platform that facilitates death receptor
oligomerization [43,44]. In addition, the polarized growth in the
presence of extracellular matrix components will alter the
activation states of intracellular signaling pathways (Fig. 1g, h).
The suppression of the PI3K pathway in Caco-2 3D cultures is
likely to contribute to the enhanced TRAIL sensitivity, as
activation of this pathway correlated with TRAIL resistance in
several tumor cell lines and PI3K inhibition rendered cells more
sensitive toward TRAIL treatment [12,45,46]. Regardless of the
precise mechanism, the impact of the cell culture set-up should be
considered in any studies involving in vitro drug testing.
Expression analyses revealed that oncogenic Ras induced the
strong upregulation of cIAP2 in Caco-2tet cells. Alterations in
IAPs are found in many types of human cancer and associated
with chemoresistance, disease progression and poor prognosis
[47,29]. In intestinal epithelial cells, Ras was shown to cause
Figure 4. Inducible expression of oncogenic K-RasG12V in Caco-2tet cells. (a) Caco-2tet vector control and K-RasG12V cells were treated with
2 mg/ml doxycycline for 72 h (+dox). Cells were harvested and GFP fluorescence was analyzed by flow cytometry. Non-induced cells were used as a
control (2dox). (b) Caco-2tet vector control and K-RasG12V cells were grown in 2D and treated with doxycycline for the indicated times prior to lysis.
GFP, Ras, pERK (T202/Y204) and ERK levels were determined by Western blotting. Tubulin was detected as a loading control. All panels shown are
from the same blot. (c) Caco-2tet vector control and K-RasG12V cells were seeded into 3D cultures in the absence or presence of doxycycline. Three
days post seeding lumen expansion was induced by addition of 100 ng/ml CTX. Cultures were fixed three days later and stained with E-cadherin-
specific antibody (green), phalloidin (red) and DAPI (nuclei; blue). Shown are confocal sections of representative cysts (scale bar: 10 mm).
doi:10.1371/journal.pone.0107165.g004
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Figure 5. Oncogenic K-Ras protects Caco-2tet cells from DbaEGFR-scTRAIL induced apoptosis. (a–c) Caco-2tet vector control and K-Ras
G12V
cells were seeded into 3D cultures in the presence of doxycycline. Three days later, cultures were treated with DbaEGFR-scTRAIL. (a) Viability was
measured 72 h later by MTT assay and normalized to the untreated control (n = 3). (b) 24 h after treatment with 1 nM DbaEGFR-scTRAIL, cells were
fixed and stained for DNA strand breaks. Tunel-positive cells were counted (n = 2). (c) Caspase 3/7 activity was measured after 24 h treatment with
1 nM DbaEGFR-scTRAIL. Values shown were normalized to the corresponding untreated control (ut) (n = 3). (d) Caco-2tet vector control and K-Ras
G12V
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cIAP2 upregulation via a TGF-a autocrine loop [48]. Our data
are consistent with this observation and support the potential
benefit of blocking autocrine EGFR signaling in combination with
death receptor stimulation. cIAP proteins bind, but do not inhibit
caspases 3 and 7, promoting their ubiquitination and degradation
[49]. This explains the reduced caspase 3 levels observed in Caco-
2tet RasG12V cells, although this downregulation was not
significant. Smac mimetics were originally developed to block
xIAP, but they are most effective at triggering the auto-
ubiquitination and degradation of cIAP1 and cIAP2. In our 3D
CRC model, strongly reduced cIAP1 levels were detected 24 hours
after SM83 treatment, whereas cIAP2 was only transiently
downregulated, in accordance with the finding that cIAP1
downregulation causes cIAP2 upregulation by non-canonical
cells were grown in 3D cultures in the presence of doxycycline for 4 days. Cells were recovered from the 3D cultures and lysates were analyzed by
immunoblotting. Shown is one representative blot of three independent experiments. Tubulin was detected as a loading control. Specific bands are
marked by arrowheads. (e) Quantification of Western blots from (c). Protein levels were normalized to the corresponding tubulin control; levels in the
vector control were set as 1 (n = 3).
doi:10.1371/journal.pone.0107165.g005
Figure 6. The Smac mimetic SM83 sensitizes oncogenic K-Ras expressing CRC cells to DbaEGFR-scTRAIL. (a–d) Caco-2tet Ras
G12V cells
were seeded into 3D cultures in the presence of doxycycline. (a) Three days later, cultures were left untreated or treated with 5 mM SM83 or 20 mM Z-
VAD for 1 h prior to addition of 1 nM DbaEGFR-scTRAIL. Viability was measured 24 h later by MTT assay and normalized to the untreated control
(n = 3). (b) 24 h after treatment, cells were fixed and stained for DNA strand breaks. Tunel-positive cells were counted (n = 2). (c) Three days post
seeding, cultures were left untreated (ut) or treated with 5 mM SM83. Cells were recovered from the cultures 24 h later and lysates were analyzed by
immunoblotting. Shown is one representative blot of two independent experiments. Tubulin was detected as a loading control. (d) Quantification of
Western blots from (c). Protein levels were normalized to the corresponding tubulin control; levels in the untreated cultures were set as 1 (n = 2). (e, f)
HCT-116 and LoVo cells were grown in 3D cultures for six days, and then fixed and stained for F-actin and DNA (DAPI) (scale bar: 20 mm) (top panels).
Three days post seeding, cultures were left untreated or pretreated with 5 mM SM83 prior to addition of 0.05 nM DbaEGFR-scTRAIL. Viability was
measured 24 h later by MTT assay and normalized to the untreated control (bottom panels) (n = 3).
doi:10.1371/journal.pone.0107165.g006
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NFkappaB activation [32]. Therefore, the potent downregulation
of cIAP1 by SM83 appears to be sufficient to tip the balance and
restore an apoptotic response to DbaEGFR-scTRAIL. Smac
mimetics have further been reported to induce cytotoxicity as
single agents, a feature linked to the induction TNF-a synthesis
and secretion [50,51]. However, in Caco-2, HCT-116 and LoVo
cells, we did not observe any cytotoxicity in response to SM83
alone, suggesting that the increased susceptibility to death
receptor-induced apoptosis primarily stems from TRAIL receptor
signaling.
Finally, a very important aspect uncovered by our study is the
requirement for tumor cell-specific targeting of recombinant
TRAIL to elicit a potent cytotoxic response. Intriguingly, cells
surviving DbaEGFR-scTRAIL treatment in the 3D cultures
expressed very low EGFR levels. It can thus be assumed that
patients whose tumors express high EGFR levels should respond
best to DbaEGFR-scTRAIL. Directing recombinant single-chain
TRAIL molecules to tumor-specific surface antigens using a
diabody-based forced dimerization strategy is not limited to the
EGFR and together with appropriate apoptosis sensitizing agents
may be a powerful approach to efficiently kill a broad range of
cancer cells.
Supporting Information
Figure S1 DbaEGFR-scTRAIL bioactivity is superior to
scTRAIL. Caco-2 cells were grown in 3D cultures in medium
containing 10% FCS. (a, b) Three days post seeding, cultures were
left untreated (ut) or treated with 1 nM DbaEGFR-scTRAIL or
scTRAIL. (a) Cell viability was determined by MTT assay after
72 h and normalized to the untreated control (n = 3). (b) Caspase
3/7 activity was measured after 24 h. The values shown were
normalized to the untreated control (n = 3). (c, d) Three days post
seeding, cultures were left untreated (ut) or treated with 1 nM
scTRAIL, 1 nM Cetuximab or the combination of both. (c) Cell
viability was determined by MTT assay after 72 h and normalized
to the untreated control (n = 3). (d) Caspase 3/7 activity was
measured after 24 h. The values shown were normalized to the
untreated control (n = 3).
(TIF)
Figure S2 DbaEGFR-scTRAIL potently inhibits EGFR
activation. (a) Caco-2 cells grown in 3D for 3 days were left
untreated or treated with 4 nM DbaEGFR-scTRAIL or 4 nM
Cetuximab for 15 min prior to stimulation with EGF (10 ng/ml)
for 10 min. Phosphorylated and total proteins were detected by
immunoblotting. Tubulin was detected as a loading control. (b)
Quantification of Western blots from (a). Shown is the ratio of
phosphorylated EGFR to total EGFR; levels in the untreated
control were set as 1 (n = 2).
(TIF)
Figure S3 Downregulation of cIAP1 and cIAP2 by SM83.
Caco-2tet RasG12V cells grown in 2D for 72 h in the presence of
dox followed by treatment with 5 mM SM83 for the indicated time
points prior to lysis. Proteins were analyzed by immunoblotting
using the indicated antibodies. Tubulin was detected as a loading
control.
(TIF)
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